Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
Phase 2
26
about 4.3 years
18+
1 site in CT
What this study is about
This trial is testing a treatment called Sipuleucel-T given with bipolar androgen therapy to men with metastatic castration-resistant prostate cancer. The goal is to see how well the Sipuleucel-T vaccine works when combined with bipolar androgen therapy.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Sipuleucel-T
- 2.Take Testosterone Cypionate
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
sipuleucel-T, Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers) (Androgen Receptor Agonists)
injection, intramuscular
Secondary: To assess safety and tolerability to BAT+ Sipuleucel-T, To determine PSA50 response rate to BAT + Sipuleucel-T, To determine ex vivo cytokine profiles with BAT + Sipuleucel-T, To determine objective response rate (ORR) to BAT + Sipuleucel-T, To estimate overall survival (OS), To estimate radiographic progression free survival (rPFS)
Oncology